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1. BACKGROUND 
 
1.1 Adaptive immunity and antigen presentation 
  
1.1.1 Adaptive immunity 
The immune system is a host defense system comprising many biological 
structures and processes within an organism that protects against disease. 
The immune system can be classified into subsystem such as innate 
immune system, that provides the first line of defense against infection 
and adaptive immune system.  
The innate responses call the adaptive immune responses into play, and 
both work together to eliminate the pathogens. Unlike innate immune 
responses, the adaptive responses are highly specific to the 
particular pathogen that induced them. They can also provide long-
lasting protection. The function of adaptive immune responses is to 
destroy invading pathogens and any toxic molecules they produce. 
Because these responses are destructive, it is crucial that they are made 
only in response to molecules that are foreign to the host and not to the 
molecules of the host itself. The ability to distinguish what 
is foreign from what is self in this way is a fundamental feature of the 
adaptive immune system. 
The adaptive immune response creates immunological memory after an 
initial response to a specific pathogen and leads to an enhanced response 
upon subsequent encounters with that pathogen.  
The cell types mediating adaptive immunity are B and T lymphocytes.  
B lymphocytes develop in the bone marrow from hematopoietic 
precursor cells. When immature B cells binds antigen through B cell 
receptor, the lymphocytes will proliferate and differentiate in plasma 
cells that produce antibodies. They are glycoproteins that neutralize 
viruses or bacteria by activating the complement system through the 
classical pathway. Each immunoglobulin molecule is made up of two 
heavy chains and two light chains joined by disulfide bonds and 
generally recognizes a small region on the surface of a large molecule, 
named epitope (Padlan et al., 1994).  
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1.1.2 Cell-mediated immune responses: T lymphocytes 
T lymphocytes derive from the multipotent hematopoietic stem cells in 
the bone marrow. The progenitor cells migrate from the bone marrow via 
blood to the thymus where they mature.  
Developing T cells, named thymocytes, undergo different changes in the 
status of T cell receptor genes, in the expression of T cell receptor or cell-
surface proteins such as CD3 complex and co-receptor CD4 and CD8. 
Two distinct lineages of T cells-α:β and Ɣ:δ which have different types 
of T cell receptors chains, are produced early in T-cell development.  
When progenitor’s cells first enter the thymus from the bone marrow, 
they lack most of the surface molecules characteristic of mature T cells 
and their receptor genes are not rearranged. Interactions with the thymic 
stroma trigger an initial phase of differentiation, but T cells do not 
express any of the three cells surface markers (CD3, CD4 or CD8). For 
this reason these cells are called double negative thymocytes.  
These cells undergo different rearrangements up to be double positive 
thymocytes (Pang et al.,2010). 
Lymphoid precursors are triggered to proliferate and become thymocytes 
committed to the T-cell lineage through interactions with the thymic 
stroma. The different stages of development are characterized by the 
expression of particular cell-surface proteins, which change until the 
development of CD8 or CD4 positive single cells.  
Once T cells have completed their development in the thymus, they enter 
the bloodstream.  
On reaching a peripheral lymphoid tissue, they leave the blood to migrate 
through the lymphoid tissue, returning via the lymphatics to the 
bloodstream to recirculate between blood and peripheral lymphoid 
tissues. Mature recirculating T cells that have not yet encountered their 
specific antigens are known as naïve T cells. When a naïve T cell 
recognizes its specific antigen on the surface of mature dendritic cell, it 
ceases to migrate and differentiate in effector T cell. 
After expansion and differentiation, the effector T cells exit the efferent 
lymphatics and reenter the bloodstream, through which they migrate to 
the sites of infection.  
These effector cells can be divided into two classes: one carrying the co-
receptor CD8 on its surface and the other bearing the co-receptor CD4. 
CD8 is carried by cytotoxic T cells which recognize peptides loaded on 
the MHC class I complex,  via their heterodimeric receptor whereas CD4 
is carried by T cells whose function is to activate other cells of the 
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immune system and recognize peptides loaded on the MHC class II 
complex through their specific receptors.  
CD4 is a single polypeptide, folded into four external immunoglobulin-
related domains. It has a unique strand topology between domains 1 and 
2 (D1 and D2) and between domains 3 and 4 (D3 and D4). The MHC 
binding region on CD4 is located mainly on the lateral face of the D1 
domain and CD4 binds to a hydrophobic crevice formed in the junction 
of the α2 and β2 domains of the MHC class II molecule (Zamoyska et al., 
1998). The D1 and D2 domains of CD4 are intimately connected. The G-
strand of D1 extends directly into the A-strand of D2, and a substantial 
interface is buried between these two domains.  The crystal structure of 
fragment of rat CD4 consisting of the third and fourth extracellular 
domains (D3D4) reveals that this fragment is strikingly similar to the 
D1D2 fragment (Leaky, 1995). The intracellular portion of CD4 interacts 
strongly with a cytoplasmic tyrosine kinase called Lck and brings Lck 
close to the intracellular signaling components associated with the T cell 
receptor.  
The structure of CD8 is quite different. It is a disulfite-linked dimer of 
two different chains, called α and β, each containing a single Ig-like 
domain linked to the membrane by a segment of extended polypeptide. 
This protein segment is extensively glycosylated, to maintain it in an 
extended conformation and protect it by proteolytic cleavage. 
CD8 binds weakly to an invariant site in the α3 domain of MHC class I 
molecule and form interactions with the residues in the base of the α2 
domain.   
The CD8 binding site to the MHC class I complex is formed by 
interaction between CD8 α and β chains.  
The binding strength of CD8 to MHC I molecule is influenced by the 
glycosylation state of the CD8 molecule. Indeed, an increased number of 
sialic acid residues added to the CD8 carbohydrate structure decrease the 
strength of the interaction. Given that the pattern of sialylation of CD8 
changes during the maturation of T cells and upon activation, studies 
suggest that   this process may have a role in modulating antigen 
recognition (Moody ., 2003).  
Antigen recognition by T cells receptors happens when peptides are 
bound to MHC molecules (Fig 1). 
MHC class I and MHC class II molecules are closely related in overall 
structure but differ in their subunit composition.  
MHC class I molecules consist of two polypeptides chains. One chain, 
the α chain, is encoded in the MHC and is non covalently associated with 
a smaller chain, β2-microglobulin, which is not polymorphic and is 
encoded on different chromosomes.  
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The complete molecule has four domains, three formed from the MHC-
encoded α chain and one contribute by β2-microglobulin. The α3 domain 
and β2-microglobulin closely resemble Ig-like domains in their folded 
structure. The folded α1 and α2 domains form the walls of a cleft on the 
surface of the molecule; this is where the peptide binds and is known as 
the peptide-binding cleft or peptide- binding groove (Bouvier et al., 
2003). 
MHC class II molecules consists of a non-covalent complex of two 
chains α and β, both of which span the membrane. Each chain has two 
domains and the two chains together form a compact four-domain 
structure similar to that of the MHC class I molecule. (Fremont et al., 
1996) 
In both MHC class I and class II molecules, bound peptides are 
sandwiched between the two α-helical segments of the MHC molecule. 
The peptide is bound as an integral part of the MHC molecule’s structure 
and MHC molecule are unstable when peptides are not bound.  
Peptides that bind to MHC class I molecules are usually 8-10 amino 
acids long.  
These interactions give MHC class I molecules a broad peptide-binding 
specificity. In addition MHC molecules are highly polymorphic. There 
are hundreds of different versions, or alleles, of the MHC class I genes in 
the human population. The main differences between allelic MHC 
variants are found at certain sites in the peptide-binding cleft, resulting in 
different amino acids in the key peptide-interaction sites. In consequence, 
the different MHC variants preferentially bind different peptides 
(Bouvier et al., 1994). 
The peptide binding for the MHC class II molecules is different from 
MHC class I. Natural peptides that bind to MHC class II molecules are at 
least 13 amino acids long and can be much longer.  
The peptide lies in an extended conformation along the peptide-binding 
cleft. It is held (1) by peptide side chains that protrude into shallow and 
deep pockets lined by polymorphic residues (2) by interactions between 
the peptide backbone and side chains that protrude into shallow and deep 
pockets lined by polymorphic residues (3) by interactions between the 
peptide backbone and side chains of conserved amino acids that line the 
peptide-binding cleft in all MHC class II molecules (Conant et al., 2003).  
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Figure 1: The binding sites for CD4+ and CD8+ on MHC class II and 
class I molecules. 
The binding site for CD4+ lies at the base of the β2 domain of an MHC 
class II molecule, in the hydrophobic crevice between the β2 and α2 
domains. The binding site for CD8+ lies in a similar position to that of 
CD4+ in the MHC class II molecule, but CD8+ binding also involves the 
base of α1 and α2 domains (from Janeway’s Immunobiology 8th edition 
2012).  
 
CD8+ cytotoxic cells (CTLs) are important in the defense against 
intracellular pathogens, especially viruses. Virus-infected cells display 
fragments of viral proteins, on the surface of MHC class I complex which 
are then recognized and then killed by cytotoxic T lymphocytes.  Perhaps 
because the effector action of these cells is so destructive, naïve CD8+ T 
cells require more co-stimulatory activity to become activated. The 
activation provides the involvement of mature dendritic cells, which have 
high intrinsic co-stimulatory activity. In some viral infections, dendritic 
cells become sufficiently activated to directly induce CD8+ T cells to 
produce the IL-2 required for their proliferation and differentiation, 
without the support of CD4+ effector cells.  In the majority of viral 
infections, however, CD8+ T cell activation requires additional help, 
which is provided by CD4+ effector T cells.  Effector CD4+ T cells that 
recognize related antigens presented by the antigen-presenting cells can 
amplify the activation of naïve CD8+ T cells by further activating the 
antigen presenting cell. CD4+ T cells also produce abundant IL-2 and 
thus help drive CD8+ T cell proliferation (Weninger et al., 2002). 
Cytotoxic CD8+ T cells lead to the death of the target cells by apoptosis. 
The killing steps require the receptor binding and the directed release of 
cytotoxic granules. Such proteins are stored in these granules in an active 
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form, but conditions within the granules prevent them from functioning 
until after their release. One of these cytotoxic proteins, known as 
perforin, act in the delivery of the contents of cytotoxic granules to 
target-cell membranes.  
Another class of cytotoxic proteins comprises a family of serine protease, 
called granzymes. Still, another class of cytotoxic CD8+ T cells is 
granulysin, which is able to induce apoptosis.  
However, most CD8+ cytotoxic T cells also release the cytokines IFN-Ɣ, 
TNF-α and LT-α which contribute to host defense in several ways. IFN-
Ɣ inhibits viral replication directly and induces an increased expression 
of MHC class I molecules and of other proteins that are involved in the 
peptide loading of these newly synthesized MHC class I molecules in 
infected cells. This increases the chance that infected cells will be 
recognized as target cells for cytotoxic attack.  
IFN-Ɣ also activates macrophages, recruiting them to the site of infection 
both as effector cells and as antigen-presenting cells. TNFα and LTα can 
synergize with IFN-Ɣ in macrophage activation (Prezzi et al., 2001).  
In contrast with CD8+ T cells, CD4+ T cells differentiate into several 
subsets of effector T cells with a variety of different functions: TH1, TH2, 
TH17 and regulatory T cells.  
TH1 cells help control bacteria that can set up intra-vescicular infections 
in macrophages, such as the mycobacteria. These bacteria are taken up by 
macrophages in the usual way but can evade the killing mechanism. If a 
TH1 cell recognizes bacterial antigens displayed on the surface of an 
infected macrophage, it will interact with the infected cell to activate it, 
stimulating the macrophage’s micro-biocidal activity thereby enabling to 
kill its resident bacteria.  
TH2 cells help to control infections by parasites through promoting 
responses mediated by eosinophils, mast cell and the IgE antibody 
isotype by promoting an immunity barrier on the mucosal surfaces 
(Bluestone et al., 2003). 
The TH1 and TH2 subsets are distinguished principally by their 
production of specific cytokines, such as interferon (IFN-Ɣ) and IL-2 by 
TH1 cells, and IL-4 and IL-5 by TH2 cells.  
TH17 cells secrete IL-17 family cytokines that induce local epithelial and 
stromal cells to produce chemokines that recruit neutrophils to sites of 
infection early in the adaptive immune response. (Littman et al., 2010) 
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All effector T cells are involved in activating their target cells to make 
responses that help clear pathogen from the body. The other CD4+ T 
cells found in the periphery have a different function. These are the 
regulatory T cells, whose function is to suppress T-cell responses. Two 
main groups of regulatory T cells are recognized. One subset becomes 
committed to a regulatory fate in the thymus; they are known as the 
natural regulatory T cells. Other subsets of CD4+ regulatory T cells with 
different phenotypes are thought to differentiate from naive CD4+ T cells 
in the periphery under the influence of particular environmental 
conditions. This group is known as induced regulatory T cells (Bluestone 
et al., 2003). These cells are distinguished by expression of transcription 
factor FoxP3 and cell-surface CD4 and CD25 and are produced when 
naïve T cells are activated in the presence of cytokine transforming 
growth factor-β (TGF-β) alone and in the absence of IL-6 and other pro-
inflammatory cytokines.  
The hallmark of the acquired immune system is memory. It results from 
the clonal expansion and differentiation of the antigenic-specific 
lymphocytes that confer immediate protection in peripheral tissues and 
mount recall responses to antigens in secondary lymphoid organs 
(Sallusto et al., 2004). Protective immunity is mediated by effector 
memory T cells (TEM) that migrate to inflamed peripheral tissues and 
display immediate effector function. By contrast, reactive memory is 
mediated by central memory (TCM). Although these cells which home to 
lymphoid organs, have little or no effector function, they readily 
proliferate and differentiate to effector cells in response to antigenic 
stimulation (Sallusto et al.,1999).  
Human TCM are CD45R0+ and costitutively express CCR7 and CD62L, 
two receptors that are also characteristic of naïve T cells. Following TCR 
triggering, TCM produce mainly IL-2, but after proliferation they 
efficiently differentiate to effector cells and produce large amount of 
IFNƔ or IL-4.  
Human TEM are memory cells that have lost the constitutive expression of 
CCR7, are heterogeneous for CD62L expression and display 
characteristic sets of chemokine receptors and adhesion molecules that 
are required for homing to inflamed tissues. When compared to TCM, TEM 
are characterized by rapid effector function. CD8+ TEM cells carry large 
amounts of perforin and both CD4+ and CD8+ produce IFN-Ɣ, IL-4 and 
IL-5 within hours following antigenic stimulation. In vivo antigens 
stimulate TCM  and TEM in different ways. TCM can be stimulated by 
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mature dendritic cells whereas TEM can be stimulated by antigen 
presented by non-professional APC cells (Gunzer et al., 2000).  
 
1.1.3 Antigen processing and presentation 
MHC class I and class II molecules are similar in function: they present 
peptides at the cell surface to CD8+ and CD4+ T cells, respectively. 
These peptides originate from different sources: intracellular for MHC 
class I molecules and exogenous for MHC class II molecules and they 
are obtained by different pathways.    
The classical pathway for presenting short peptides to CD8+ T cells in 
the context of MHC class I molecule involves cytosolic digestion of 
proteins to optimal length (8-10 amino acids) or N terminal extended 
proteins by the proteasome (Donoso et al., 2005; Tsvetkov et al., 2010). 
A typical proteasome is composed of one 20S catalytic core and two 19S 
regulatory caps, one at each end; both the core and the caps are multi-
subunit complexes of proteins. The 20S core is a large cylindrical 
complex of some 28 subunits, arranged in four stacked rings of seven 
subunits each. It has a hollow core linked by the active site of proteolytic 
subunits. The 19S regulatory cap serves to recognize ubiquitinated client 
proteins and is thought to play a role in their unfolding and translocation 
into the interior of the 20S CP, which contains catalytic threonine 
residues on the surface of a chamber formed by two –rings. The two 
inner rings of the 20S proteasome core are composed of constitutively 
expressed proteolytic subunits called β1, β2, and β5 which form the 
catalytic chamber. These constitutive subunits are sometimes displaced 
by three alternative catalytic subunits, called LMP2, LMP7 and MECL-1 
and are induced by interferons (Cascio et al., 2002). 
The proteasome comprises two forms: constitutive proteasome present in 
all cells and the immunoproteasome present in cells stimulated with 
interferons.  The replacement of the β subunits by their interferon-
inducible counterparts alters the enzymatic specificity of the proteasome 
such that there is increased cleavage of polypeptides after hydrophobic 
residues and decreased cleavage after acidic residues. This produces 
peptides with carboxyl-terminal residues, which are preferred anchor 
residues for binding to most MHC class I molecules and are also 
preferred structures for transport by TAP( transporter associated with 
antigen). The production of antigenic peptides of the right length is 
increased by a modification of the proteasome induced by interferon-Ɣ. 
This is the binding to the proteasome of a protein complex called the 
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PA28 proteasome-activator complex. PA28 is a six or seven-membered 
ring composed of two proteins, PA28α and PA28β, both of which are 
induced by INF-Ɣ. A PA28 ring can bind to either end of the 20S 
proteasome core in place of the 19S regulatory cap, and acts to increase 
the rate at which peptides are released. In addition to simply providing 
more peptides, the increased rate of flow will allow potentially antigenic 
peptides to escape additional processing that might destroy their 
antigenicity.  
Proteins are often tagged for degradation by the attachment of the 
ubiquitin molecule. Ubiquitination is a post-translational modification in 
which the 76 amino acid protein ubiquitin is covalently attached via its 
carboxyl terminus to Lys residues in target proteins. Ubiquitin can be 
attached to proteins as a single entity on one or multiple sites, yielding 
mono and multi-monoubiquitylated proteins. Poly-ubiquitylation is the 
formation of a ubiquitin chain on target proteins. The formation of poly-
ubiquitin chains involves isopeptide bond connection between the 
carboxyl-terminal glycine residue of ubiquitin and an internal K residue 
or the amino-terminal (M1) of another ubiquitin. Different lysine 
residues could be involved such as Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48 and Lys63 thereby creating a large variety of ubiquitin chains (Fig 
2).  
Ubiquitin chains are assembled by a three-step enzymatic cascade 
comprising E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating 
enzymes and E3 ubiquitin-ligating enzyme. The involvement of one 
lysine rather than another can address different subcellular processes.  
Indeed, Lys48-linked ubiquitin chains are identified on proteasome 
substrate and Lys63- linked ubiquitin chains have a role in DNA repair, 
DNA damage response and cytokine signaling (Kulathu and Komander ., 
2012). 
Ubiquitination regulates different immune functions focusing on PRR 
(pattern-recognition receptor) signaling in innate immunity inflammation, 
DC maturation, T cell differentiation and tolerance. Especially, it is 
highly important to mark proteins that can be presented by MHC class I 
complex.  In this way these target proteins can be processed by 
proteasome and elicit a CD8+ T cell response.  
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Figure 2: Forms of ubiquitination 
a) The seven Lys residues and Met1 of ubiquitin are show in stick 
representation, and amino groups that are modified with ubiquitin 
during chain formation are shown as blue spheres. b) Overview of 
different forms of ubiquitination. A substrate can be modified by 
mono-, multi-mono or polyubiquitin (from Kulathu and Komander ., 
2012).  
 
The main substrates for the proteasome are cytosolic endogenous 
proteins and viral proteins for the classical MHC class I pathway and 
exogenous proteins re-trotranslocated from phagosomes or endosomes to 
the cytosol, for cross presentation (Raghavan et al., 2008; Blum et al., 
2013). The peptides are transported into the ER by TAP (transporter 
associated with antigen processing) and where needed N terminal cleaved 
to optimal length peptides by endoplasmic reticulum aminopeptidase 
1(ERAP1; ERAAP in mice) and ERAP2. These peptides associate with 
the protein-loading complex (PLC) which differs slightly between HLA 
allotypes, but usually involves: tapasin, endoplasmic reticulum protein 57 
(Erp57), calnexin (CAL), calreticulin (CRT) and the MHC-I heterodimer. 
Loading of high affinity peptides stabilize the MHC-I molecule and 
releases PLC, allowing MHC-I: peptide complexes to traffic through the 
Golgi to the cell surface for presentation to CD8+ T cells (Hammer et al., 
2006) (Fig 3).  
The antigens presented by class II peptides are derived from extracellular 
proteins. These extracellular foreign antigens, such as bacteria or 
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bacterial antigens have been taken up by an antigen-presenting cell such 
as macrophage or immature dendritic cell. In other case, the source of 
antigen may be bacteria or parasites that have invaded the cell to 
replicate in intracellular vesicles. In both cases the antigen-processing 
pathway is the same. The pH of the endosomes containing the engulfed 
pathogens decreases progressively, activating proteases within the 
vesicles to degrade the engulfed material. At some point on their pathway 
to the cell surface, newly synthesized MHC class II molecules pass 
through such acidified vesicles and bind peptide fragments of the antigen, 
transporting the peptides to the cell surface.    
The biosynthetic pathway for MHC class II molecules starts with its 
translocation into ER. However, they must be prevented from binding 
prematurely to peptides transported to ER lumen or to the cell’s own 
newly synthesized polypeptides.  
Binding is prevented by the assembly of newly synthesized MHC class II 
molecules with a membrane protein known as the MHC class II 
associated invariant chain (Ii, CD74).  
When antigen peptides are ready to be loaded, the proteases cleave the Ii 
in the acidic vesicles, leaving the CLIP (class II-associated invariant 
chain peptide) bound to the MHC class II molecule. Pathogens and their 
proteins are broken down into peptides within acidified endosome, but 
these peptides cannot bind to MHC class II molecules that are occupied 
by CLIP. The class II-like molecule HLA-DM binds to MHC class II: 
CLIP complexes, catalyzing the release of CLIP and the binding of 
antigenic peptides.  
A second atypical MHC class II molecule, called HLA-DO is produced 
in thymic epithelial cells and dendritic cells. This molecule is a 
heterodimer of the HLA-Doα chain and HLA-Doβ chain. HLA-DO acts 
as negative regulator of HLA-DM, binding to it and inhibiting both the 
HLA-DM- catalyzed release of CLIP and the binding of other peptides to 
MHC class II molecules. Expression of HLA-Doβ chain is not increased 
by IFN-Ɣ, whereas the expression of HLA-DM is. Thus, during 
inflammatory response, in which IFN-Ɣ is produced by T cells and NK 
cells, the increased expression of HLA-DM is able to overcome the 
inhibitory effects of HLA-DO (Fig 3). 
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Figure 3: Antigen presentation on MHC class II and MHC class I 
molecules. 
a) MHC class II pathway: MHC-Ii α and β chains are translated by 
ER-associated ribosomes, they are brought together and stabilized 
into MHC II heterodimers by the Invariant chain. It forms a trimer 
and stabilizes three heterodimers to form a nonamer. Ii provides the 
endolysosomal sorting sequence, which leads the MHC II-Ii 
complexes via the trans-Golgi network to mature endosomes. MHC 
II-Ii can also reach the cell surface and be transported back into 
endosomes. In the acidic environment of the late endosome, MHC 
class II compartment (MIIC) and phagolysosomes cathepsins cleave 
Ii sequentially, leaving the CLIP peptide in the peptide-binding 
groove of MHC II molecules. HLA-DM associates with MHC II-
CLIP, causing a conformational change that releases CLIP and 
allows cathepsin cleaved peptides to bind to MHC II. Protein 
substrates for cathepsins and other endosome resident proteases are 
delivered to the late endosomes by phagocytosis, endocytosis, and 
autophagy, allowing both exogenous and endogenous proteins to be 
presented on MHC-II. Binding of high affinity peptides releases HLA-
DM and frees MHC II-peptide molecules to traffic to the cell surface 
for presentation to CD4+ T cells. 
b) MHC class I pathway:  MHC-I molecules present short peptides 
which are derived from native proteins, defective ribosomal products 
(DRiPs), viral proteins and retro-translocated exogenous proteins 
(for cross-presentation). The main source of peptides for MHC-I 
a) b) 
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loading are the degradation products of the proteasome, which 
cleaves proteins in the cytosol to peptides that are transported via 
TAP to the ER. When in the ER peptides can be trimmed by ERAP-1 and 
ERAP-2 or they can bind directly to MHC-I heterodimers in protein 
loading complexes (PLCs). Initially MHC-I heterodimers in the ER 
are stabilised by interactions with calnexin (CXN), which allows the 
binding of β2microglobulin, and then association with calreticulin 
(CRT), tapasin, and ERp57. Tapasin stabilizes MHC-I heterodimers 
in the PLC in close proximity with TAP, which supplies cytosolic 
peptides. Only on binding of high affinity peptides are tapasin and 
the PLC released from MHC-I-peptide molecules, which are then 
allowed to traffic to the cell surface for presentation of peptides to 
CD8+ T cells (Janeway’s Immunobiology 8th edition 2012). 
   
An interesting link, termed cross-presentation, exists between the two 
pathways. In this process extracellular antigens, which are normally 
loaded on MHC class II complex, are instead presented by MHC class I 
molecules. The proposed pathway for cross-presentation could be divided 
into two main categories: those dependent on TAP and proteasome and 
those relatively independent of these factors (Raghavan et al., 2008). The 
latter, termed vacuolar pathway is where cathepsin S is the principal 
protease that generates antigenic peptides in the endo-lysosome and binds 
to MHC class I (Fig 4a). 
For TAP and proteasome-dependent presentation, the antigen must reach 
the cytosol. It is possible that some antigens are transported in the cytosol 
after their uptake in DCs cells through the endoplasmic reticulum 
associated protein degradation (ERAD) by Sec61, a putative translocon 
channel (Fig 4b) (Ackerman et al., 2006).  
ERAD is a complex process through which folding-defective proteins are 
selected and ultimately degraded by the ubiquitin-proteasome system. It 
can be envisioned as encompassing four distinct, coupled steps: 1) 
substrate recognition; 2) dislocation across the lipid bilayer; 3) addition 
of poly-ubiquitin adducts; 4) degradation by the 26 S proteasome. 
At first molecular chaperones and lectins within the ER lumen interact 
with incompletely folded or unassembled clients. These factors link 
substrate recognition to the dislocation machinery by binding to 
membrane-embedded adaptors. Then, substrates are dislocated across the 
bilayer presumably through proteinaceous pores (dislocons), via a 
process coupled to the energy derived from ATP hydrolysis by VCP/p97. 
On gaining access to the cytosol, substrates are polyubiquitinated by E3 
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ligases, especially on Lys11 and these ubiquitinated substrates are 
degraded by cytosolic 26S proteasomes (Olzmann et al.,2013).   
Another mechanism that allows the transport of antigen to the cytosol 
takes place from the phagocytic, endocytic or macropinocytic 
compartments. Gagnon et al (2003) demonstrated that the phagosomal 
membranes are formed in part from the ER membrane and the ERAD 
factors and components of MHC class I peptide loading machinery are 
found together within these membranes (Fig 4c). 
 Other possible pathway provides that soluble exogenous antigens are 
retro-translocated in the cytosol from the endosomal compartment. Then 
after proteasome processing, these peptides  are re-imported back into 
endosomes via endosomal TAP that can be recruited to early endosome 
in a TLR4-Myd88 dependent manner, where peptide loading of recycling 
MHC class I occurs (Fig 4d) (Raghavan et al., 2008). 
 
  
 
 
Figure 4: Different cellular pathways for antigen cross- presentation 
a) Vacuolar TAP independent pathway: endocytosed antigens are 
proteolytically processed by cathepsin S and loaded on MHC class I 
into endosome.  
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b) Retrograde translocation model: Once in the ER, the soluble antigens 
retro-translocate into the cytosol by ERAD machinery and process 
similarly to endogenous proteins for MHC class I presentation 
c)  TAP-dependent phagosomal pathway is supported by the presence of 
ER components on phagosomes. Phagocytosed antigens use Sec61 
channel to exit from the phagosome, are processed by proteasome 
and are reimported into the phagosome for loading into MHC class I 
molecules within the phagosome. 
d) TAP-dependent endosomal pathway: antigen egress from the 
endosome by an unknown transporter and after proteasomal 
proteolysis, processed fragments are ferried back into endosome by 
recruited TAP and loaded into recycling MHC class I molecules 
(Raghavan et al.,2008) 
 
1.2 Invariant chain (Ii) and its function 
 
Ii is a non-polymorphic type II trans-membrane protein, first identified as 
the chaperone for MHC class II molecules (Blum et al., 2013). The main 
function of Ii is to stabilize the interaction of the α and β chains as they 
are formed in the endoplasmic reticulum (ER) and to occupy the peptide-
binding groove of the MHC class II molecules. Ii inhibits peptide loading 
within the ER and targets MHC class II to the endosomal network via its 
endolysosomal targeting sequence signal peptide (ESS; Sandoval et al., 
1994). After its synthesis, Ii is inserted in the ER thanks to its internal 
transfer peptide and its transmembrane domain.  The complex Ii-MHC 
class II goes through Golgi and reaches the peripheral endocytic pathway 
where Ii is sequentially cleaved by cathepsins to CLIP peptide, which is 
then displaced by exogenous peptides for presentation to CD4+ T cells. 
In humans Ii is expressed as four different isoforms named according to 
their alternative molecular weights in kilodalton: Ii p33, Ii p35, Ii p41 
and Ii p43. The isoforms are produced from a single gene through a 
combination of alternative splicing and alternative translation (Sand et 
al., 2014). The short isoforms, denoted p33 and p35, differ from the long 
isoforms, denoted p41 and p43, by a 64 amino acid insertion encoded by 
the alternatively spliced exon 6 in the C terminal luminal domain which 
has been shown to regulate the activity of cysteine proteases (Sand et al., 
2014). In addition to this splicing variation, an alternative initiation 
codon gives rise to a 16 amino acid N-terminal extension present in the 
p35 and the p43 isoforms of human Ii. This additional segment confers 
retention in the ER consisting of three successive arginine residues (Fig 
5). 
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The predominant form is the p33 form in humans that in mice is is 
termed p31.  
Several post-translational modifications of the CD74 protein have been 
identified. N- and O-glycosylation has been reported for murine and 
human CD74. Furthermore, modification of a specific serine residue with 
glycosaminoglycans has been described (Miller et al., 1988). Human 
invariant chain is phosphorylated within its cytoplasmic domain.  
Ii is capable of assembling into homo-trimers (Roche et al., 1991). The 
region responsible for its self-association is mapped between 118 and 
193 residues. This trimerization domain is organized in a α-helical coiled 
structure, forming a scaffold that allows interaction with three MHC-II 
heterodimers (α: β) (Cresswell et al., 1996) 
Other domains in the Ii structure are also important for its function.  
The cytoplasmic tail of Ii contains two endosomal targeting sequences 
within amino acid residues 12-29 and the deletion of this segment reveal 
the presence of a second endosomal targeting sequence, located within 
the first 11 amino acid residues (Pieteres et al., 1993).  The 
transmembrane domain might contribute to stable homotrimer formation 
(Stumptner-Cuvelette and Benaroch., 2002) and is also required for 
efficient delivery to endocytic processing compartment containing a 
signal distinct from the Ii cytoplasmic tail (Odorizzi et al., 1994). 
This domain has long been implicated in both correct folding and 
function of the MHC class II complex. Specific mutations in the 
transmembrane domain have been shown to disrupt MHC class II 
functions such as mature complex formation and antigen presentation.  
CLIP domain (amino acids 86-100) is important to prevent the premature 
binding of antigenic peptides while KEY (amino acids 76-79) plays an 
important role in CLIP loading on MHC class II peptide binding groove 
(Chen et al., 2012). 
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Figure 5: The known functional domains of Ii  
a) Ii is represented interacting with MHC class II (green) and with 
another Ii chain via its trimerisation domain (red). (b) Aligned 
representation of murine Ii and the main human isoforms of Ii. The key 
domains are labeled and numbered according to their amino acid 
position along the murine Ii sequence. The 30 amino acid cytosolic tail at 
the N-terminal of the Ii encodes the endolysosomal sorting sequence 
(ESS; a di-leucine based signal). Attached to this are a type-II 
transmembrane region (amino acids 31-54) and a large luminal domain, 
which contains the KEY motif and CLIP (class II-associated invariant 
chain peptide) - the residues that interact with MHC Class II molecules - 
and a trimerisation domain (aminoacids 118-193). CLIP is the section of 
Ii that sits directly within the binding groove of MHC class II molecules 
and KEY has a role in peptide exchange within this binding groove. 
Human p35 and p43 isoforms of Ii (numbered according to their 
molecular weight) have an additional 17 amino acids at the beginning of 
Ii, which encodes an ER retention sequence (ERR). Human p41 and p43 
isoforms contain an additional exon.  
 
Ii is a complex protein with many functional domains and roles within 
the cell, not all of which are involved in antigen processing. In much the 
same way as it interacts with and controls the trafficking of MHC-II 
molecules, it acts as a chaperone for CD1d (Kang and Cresswell, 2002) 
and for the neonatal Fcγ receptor molecules (Ye et al., 2008), both of 
which are structurally related to MHC-II. Ii has been shown to associate 
 
22 
 
with CD70 (a CD27 ligand), by mediating its delivery to the 
immunological synapse (Zwart et al., 2010), and it binds to myosin-II, 
thereby limiting cell migration in DCs (Faure-Andrè et al., 2008). Ii also 
functions as a surface receptor for macrophage migration inhibitory 
factor (MIF) (Matza et al., 2002).  The cytosolic domain of Ii is released 
upon binding MIF and it acts as an essential transcription factor in B-cell 
maturation and survival, by signaling through NfκB and by upregulating 
anti-apoptotic markers such as BCL-Xl and BCL-2 (Starlets et al., 2006).  
Ii regulates the trafficking of additional molecules, such as angiotensin II 
type I receptor (AT1). It associates with AT1 and impedes its 
intracellular trafficking (Szaszak et al., 2008). Ii regulates the B cell 
development, DC motility and thymic selection.  
 
1.3 Genetic vaccines and how to improve immune response 
 
1.3.1 Why genetic vaccines? 
Vaccines have been undeniably successful at inducing immune 
responses, most notably neutralizing antibodies that prevent viral or 
bacterial infections. However, to protect against more complex pathogens 
such as HIV, hepatitis C, malaria, tuberculosis (TB), it might be 
necessary to elicit also CD8 T cells of sufficient magnitude and effector 
function to recognize and rapidly clear infected cells before the pathogen 
establishes a chronic infection. 
Pre-clinical and clinical evidence supports the role of T cell immunity 
and in particular CD8+ T cells in the control and/or clearance of these 
diseases (Kim and Ahmed., 2010). Therefore, a rapidly expanding field 
in vaccinology is the development of so-called genetic vaccines. These 
are designed to induce antigen-specific CD4+ and CD8+ T cells of 
sufficient magnitude and necessary phenotype or effector function that 
directly contribute to pathogen clearance, rather than only CD4+ T cell 
help for B cells leading to protective antibody responses.  
One way to induce a T cell response against a given antigen is to express 
that antigen intracellularly, along with suitable pathogen-derived innate 
activators, through gene delivery; genetic or gene-based vaccines attempt 
to use physiological antigen processing and MHC class I presentation to 
activate a CD8+ T cell response.  
DNA vaccines were initially thought to be the ideal way to induce T cell 
responses. 
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1.3.2 DNA vaccination  
 
DNA vaccine consists of a plasmid encoding a pathogenic gene and all 
elements needed to transcribe this gene in mammalian cells.   
The use of DNA as a vaccine determines increased protein synthesis, 
augmented T cell help and MHC class I presentation and the production 
of specific cytokines and pathogen associated molecular patterns that 
increase innate immune activation leading to T-cell response as well as 
the production of antibodies against the encoded protein (Carvalho et al., 
2010).  
Once the sequence of the gene of interest has been optimized, inserted 
into the multiple cloning region of a plasmid backbone and delivered to 
the inoculation site through intramuscular or intradermal injection, the 
plasmid enters in the nucleus of transfected monocytes and of resident 
antigen presenting cells (APCs) by using the host cellular machinery. 
APCs have a dominant role in the inducing the immunity of DNA 
vaccines by presenting vaccine-derived endogenous peptides on MHC 
class I molecules. APC cells can do this by a direct transfection by 
plasmid vaccine, by cross presentation of cell-associated exogenous 
antigens or lastly by engulfment of apoptotic transfected cells. 
Antigen-loaded APCs travel to the draining lymph node via afferent 
lymphatic vessel where they present peptide antigens to naïve T cells via 
MHC and T cell receptor (TCR) in combination with costimulatory 
molecules. In response to peptide-bound MHC molecules and co-
stimulatory secondary signals, activated CD4 T helper cells secrete 
cytokines during cell-to cell interaction with B cells.  
In this way the two arms of the immune system are elicited by DNA 
immunization (Fig 6).  
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Figure 6: Cellular and humoral immunity after DNA vaccines 
The optimized sequence of the gene of interest is inserted in a plasmid 
backbone, purified and delivered to the inoculation site. Using the host 
cellular machinery, the plasmid enters the nucleus of transfected 
monocytes (1) or APC cells (2). The plasmid components initiate gene 
transcription, which is followed by protein production in the cytoplasm.  
These host-synthetized antigens could be elicited immune system through 
MHC class I or class II complexes. APCs have an important role in the 
induction of immunity of DNA vaccines by presenting vaccine 
endogenous peptide to MHC class I or cross-presentation of cell-
associated exogenous antigens: for example owing to APC engulfment of 
apoptotic transfected cells (3). 
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APC mediate the display of peptides on MHC class II molecules after 
secreted protein antigens that have been shed from transfected cells are 
processed by endocytic pathway(4). Antigen-loaded APC travel to the 
draining lymphnode (DLN) via the afferent lymphatic vessel (5) where 
they present antigens to naïve T cells via MHC and TCR (6). In response 
to peptide-bound MHC molecules, CD8+ T cells and CD4+ T helper 
cells (7) are activated. The latter ones activate also B cells. Now 
activated cells can travel through the efferent lymphatic system (from 
Kutzler and Weiner., 2008). 
.      
A series of trials of prophylactic and therapeutic DNA vaccines in 
humans against various pathogens, including HIV, HCV and malaria 
have been tested. 
Indeed, McConkey et al (2003) have demonstrated that a heterologous 
prime-boost vaccination regime of DNA administered either 
intramuscularly or epidermally, followed by intradermal recombinant 
modified vaccinia virus Ankara (MVA) induces high frequencies of 
interferon (IFN)-Ɣ secreting antigen- specific T cell responses in humans 
to a pre-erytrocytic malaria antigen, thrombospondin-related adhesion 
protein (TRAP).  
This vaccination regime determines responses that are five to ten folds 
higher than the T cell responses induced by DNA vaccine or MVA 
vaccine alone. In addition it produces a partial protection through a 
delayed parassitemia after sporozoite challenge with a different strain of 
Plasmodium falciparum. 
The use of a DNA vaccine presents a series of pros and cons. The pros 
are that, compared to conventional approaches the plasmids can be 
manufactured by generic processes, including standardized quality 
control and storage conditions that are independent of the encoded 
sequence (Carvalho et al., 2010).  They can be manipulated to co-express 
cytokines or other molecules to enhance immune response.  
The cons are that the generated T cell responses are very low magnitude 
and after incorporation of immunizing DNA, various oncogenes could be 
activated along anti-DNA antibodies. 
Different strategies have used an adjuvant to enhance immunogenicity of 
DNA vaccines in humans, but the improvement has been far too modest 
(Baden et al., 2011). 
Other possible problems regard a suboptimal delivery, poor antigen 
expression and the lack of a localized inflammatory response, all 
essential for antigen presentation and an effective immune response to 
the immunogens (Li et al., 2012).  
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1.3.3 Viral vector based vaccines 
 
An alternative powerful technology for delivering heterologous antigens 
is based on the use of viruses as vaccine vectors. It is possible to delete 
crucial region of viral genome to render the virus as replication-defective 
(Tatsis et al., 2004). Virus-derived vectors offer different advantages 
including the efficient delivery of exogenous gene into target cells, high 
level of production of proteins antigens within cells of the immunized 
host and the adjuvant effects derived from the use of viruses as vectors 
exploiting their own propriety. A number of organisms have been used 
for vector vaccines, including poxviruses, alpha viruses, and lentiviruses. 
 
Poxviruses have been used as vaccines for infectious organisms and 
tumors because they are high immunogenic and high readily engineered 
for their large capacity to insert foreign genes (at least 25kb), thus 
enabling multivalent vaccines to be created. Further they are safe in 
humans and had a series of properties including: broad tropism of the 
virus in mammalian cells, localization of the virus in the cytoplasm thus 
avowing integration risk; several routes of administration and the ability 
to induce both antibody and cytotoxic T cell response after a single 
inoculation (Folgori and Capone; 2012). Vaccines based on poxviruses 
are derived from vaccinia virus or members of the avipox genus. Indeed, 
non-replicating vectors, such as avipox or fowlpox, which confer 
extended expression times and enhanced immunogenicity, are now 
undergoing clinical trials (Mastrangelo et al., 2000). Two main types of 
approaches have been taken to enhance the safety of vaccinia virus. The 
former consists, based on scientific knowledge, to delete viral genes 
which are involved in nucleic acid metabolism, host interactions, and 
extracellular virus formation. The latter consists in successive passage of 
the virus in an unnatural host or in tissue culture, and the isolation of 
virus variants. Both approaches have led to safe vaccinia virus strains. 
The safety of vaccinia virus can also be enhanced by multiple deletions. 
This has been demonstrated by the engineering of the NYVAC strain of 
vaccinia virus (Tartaglia et al., 1992) derived from the Copenaghen strain 
of vaccinia and rendered replication incompetent by 18 specific 
engineered deletions.  
Successive passage of the virus in an unnatural host or in tissue culture, 
and the isolation of virus variants, has also lead to safer strains of 
vaccinia virus. The most notorious example is the modified vaccinia 
virus Ankara (MVA) strain which was isolated after more than 500 
passages in chicken embryo cells. MVA has lost the ability to replicate in 
mammalian cells, is a pathogenic even for immunodeficient animals, and 
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was administered without apparent incident to about 120,000 humans 
including many who were considered a poor risk for the conventional 
smallpox vaccine. MVA replication cycle is blocked at a late stage of 
morphogenesis in mammalian cells and an examination of the MVA 
genome revealed six major deletions totaling approximately 31 Kb. 
Marker transfer experiments indicate that multiple gene defects need to 
be corrected for efficient replication of MVA in mammalian cells. The 
safety of MVA has been demonstrated in pre-clinical studies of 
immunodeficient mice and immunosuppressed macaques (Wyatt et al., 
2004; Stittelaar et al., 2001) and in Phase I clinical trials evaluations of 
MVA as a next generation smallpox vaccine (Parrino et al., 2007). 
 
Another viral- vectored based vaccine entails the use of alpha viruses. 
Alpha viruses are positive-stranded RNA viruses that have a broad host 
range and therefore are capable of replicating in the cytoplasm of 
infected cells.  
The single-stranded alpha virus genome is divided into two ORFs. The 
first ORF encodes the nonstructural proteins that are translated upon 
entry of the virus into the cytoplasm and are responsible for transcription 
and replication of viral RNA. The second ORF is under the control of a 
sub-genomic promoter and normally encodes the structural proteins, 
which are responsible for encapsidation of viral RNA and final assembly 
into enveloped particles. Expression vectors have been engineered 
replacing structural genes with heterologous genes up to 5kb while 
structural proteins are provided in trans from two helper transcripts that 
lack a packaging signal. These RNA vectors, known as replicons are 
single cycle vectors incapable of spreading from infected to non-infected 
cells. Alpha virus replicon vectors are being developed as a platform 
vaccine technology for numerous viral, bacterial, protozoan and tumors 
antigens where they have been shown to be efficient inducers of both 
humoral and T cell responses. In addition, as the alpha virus structural 
proteins are not expressed in vaccine recipients, anti-vector immune 
responses are generally minimal, allowing for multiple effective 
immunizations of the same individual (Rayner et al., 2002). 
The new alpha viruses that are being developed as vaccine vectors 
include Venezuelan equine encephalitis virus (VEE), Sindbis virus (Sin), 
Semliki forest virus (SFV) and VEE-SIN chimaeras (Thornburg et al., 
2007). Several features of alpha viruses make them useful for vaccine 
development: (1) they infect a broad range of animals, including humans, 
often with mild or no symptoms.; (2) the seroprevalence to alphaviruses 
is low, thus reducing the probability of interference with immune 
responses to vectored gene products; (3)they have or may be engineered 
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to have lymph node tropism that results in effective antigen presentation 
and induction of a strong and balanced immune response (Rayner et al., 
2002). Further the immune responses are enhanced because as the self-
amplification of the vector RNA through a double-stranded RNA 
intermediates which stimulate activation of interferon cascade and 
multiple innate signaling pathways (Naslund et al., 2011). The vectors 
also induce apoptosis in some cells types and the release of apoptotic 
bodies that are efficiently taken up by antigen-presenting cells can result 
in enhanced immune cross-priming (Perri et al., 2003). There are three 
main approaches described for the use of alpha virus as vaccine vectors: 
virus-like particles, layered DNA-RNA vectors and replication-
competent vectors.  Virus-like particles are non-replicating vectors and 
are able to undergo only one cycle of expression. Layered DNA-RNA 
vectors express SFV replicon from a cDNA copy via a cytomegalovirus 
promoter. Replication-competent vectors contain as the gene of interest 
as the structural genes important for replication machinery.  Packaged 
SFV-, SIN- and VEE-based replicon vectors have been demonstrated to 
induce robust humoral, mucosal and cellular immune responses in 
animals. At the same time, there aren’t neutralizing anti-vector antibodies 
to ensure the use of these vectors as booster (Durso et al., 2007). 
The chimera VEE/SIN has been developed exploiting the replication 
proprieties of VEE and the envelope glycoprotein packaging component 
of SIN. In mice this chimera ensured a potent immune response as VEE 
its self, being it is a pathogenic virus. Also it is superior than SIN or SIN-
VEE chimera (Perri et al., 2003). Other studies in macaques showed that 
the VEE/SIN chimera elicited more potent systemic and mucosal 
immune responses to an inserted HIV envelope gene product compared 
to the SIN vector alone (Gupta et al., 2006).   
 
A specific T cell response can be also induced using recombinant 
lentiviral vectors (LV) as vaccines. LV are able to transduce non-dividing 
cells, such as dendritic cells, at high transduction efficiencies and to 
allow persistent antigen presentation through high level expression of 
transgenes and low interfering anti-vector immune responses (Breckpot 
et al., 2003). It has been shown that LV encoding HIV-1 polyepitopes 
induces CD8+ T cell response in mice (Iglesias et al., 2007). Beignon 
and colleagues (2009) showed that a prime/boost vaccination strategy 
using lentiviral vectors pseudotyped with a glycoprotein G from two non-
cross-reactive vesicular stomatitis virus serotypes elicited robust and 
broad cellular immune responses against the vector-encoded antigen, 
simian immunodeficiency virus (SIV) GAG, in cynomolgus macaques. 
Vaccination conferred strong protection against a massive intrarectal 
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challenge with SIVmac251, as evidenced both by the reduction of 
viremia at the peak of acute infection and by the full preservation of the 
CD28+ CD95+ memory CD4+ T cells during the acute phase. 
Despite the use of lentivirus as vectors ensures the advantage to deliver 
the transgenes into dendritic cells, vector integration in the host cell 
genome has provoked safety concerns. For this reason Wanisch et al 
(2009) generated an integration-deficient lentiviral vectors (IDLVs) by 
interrupting the function of integrase or its attachment sites in the vector 
backbone. Despite the integration is inhibited, the vectors continued to 
infect dividing cells and maintained durable transgene expression in non-
dividing cells (Philippe et al., 2006).  Preliminary experiments provide 
the single injection of IDLV encoding the envelope protein of either 
HIV-1 (Negri et al., 2007) or West Nile virus (Coutant et al.,2008) 
resulted in significant and prolonged immune responses against inserted 
antigen. Other reports showing that after immunization in mice with 
IDLV encoding viral or tumor antigens, antigen-specific immune 
responses were elicited (Karwacz et al., 2009).  
 
One of the most potent technologies demonstrated to induce CD8+ T cell 
response in mice, primates, and humans is based on adenovirus vector 
(Ad). 
Adenoviruses are double-stranded DNA viruses with a genome of 34-43 
kb. The linear genome flanked by two origins for DNA replication 
(ITRs) has eight units for RNA polymerase II-mediated transcription. 
The genome carries five early units (E1A, E1B, E2, E3,E4 and E5), two 
units that are expressed with a delay after initiation of viral replication 
(IX and Iva2) and one late unit(L) that is subdivided into L1-L5.  
The E1A unit activates transcription of the other viral genes. Deletion of 
E1A renders the virus replication-defective. E1A stimulates viral DNA 
synthesis, deregulates cell-cycle control by increasing the stability of p53 
and promote apoptosis unlike E1B that has anti-apoptotic activity.  
The E2 unit encodes DNA-binding proteins and a polymerase and is 
essential for viral replication. The E3 unit is nonessential for virus 
replication. E3 proteins allow the virus to escape immunosurveillance by 
reducing expression of major histocompatibility complex (MHC) class I 
determinants.  
The E4 transcription unit encodes seven polypeptides through distinct 
open reading frames (ORFs), which affect viral transcription and a 
number of host cell functions including cell proliferation and apoptosis. 
The late transcription units, divided into five subunits (L1-L5) encode as 
many as 45 different species of RNA. Products of the late transcription 
unit form the viral capsid (Rux et al., 1999).  
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Generation of adenoviral vectors where it is possible to clone the gene of 
interest (GOI) entails three steps. The first step entails the cloning of GOI 
into the shuttle vector. Shuttle vectors are commercially available. The 
most common shuttle vector is pshuttle-CMV. The second step entails 
the homologous recombination in vivo in bacteria. In particular,    the 
shuttle vector containing GOI is linearized and introduced into highly 
electro competent BJ5183 bacterial cells pre-transformed with 
supercoiled backbone plasmid vector containing most of the viral 
genome flanked by inverted terminal repeat (ITR). The third and final 
step entails virus production in packaging cell lines. In particular, PacI-
digested linearized recombinant adenoviral DNA containing GOI is 
transfected into packaging cell lines, viz, HEK-293 cells or PER.C6 cells. 
Viruses are then harvested 14-20 days later (Luo et al., 2007).  
The basic shuttle vectors have 1) resistance cassettes (Ampicillin or 
kanamycin), 2) multiple cloning sites with highest capacity to 
accommodate a transgene, 3) a promoter (usually CMV promoter) and a 
polyadenylation signal, and 4) stretches of sequence homologues to the 
backbone vectors to facilitate homologous recombination.   
The backbone vectors, instead, retain the majority of human adenovirus 
serotype 5 (Ad5) with deletions of E1 and E3 genes which create space 
for transgenes and eliminate self-replication capacity. Depending on the 
size of the gene of interest, there is the possibility to delete the E4 gene to 
have more space. It also carriers ampicillin resistance, which is lost after 
recombination with shuttle vector (Fig 7).  
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Figure 7: Schematic illustration of generating recombinant 
adenoviruses  
Three independent steps are important for recombinant adenoviruses 
production: 1) subcloning GOI into a shuttle vector which transfers the 
GOI into the pAd plasmid containing the adenoviral backbone 2) during 
homologous recombination in bacterial system, and 3) packaging 
recombinant adenoviral DNA containing GOI in 293 cells 
complementing E1 in trans. Recombinant adenoviruses are collected, 
amplified, concentrated and titrated suitable for in vivo application (from 
Luo et al., 2007).  
 
32 
 
 
Adenoviruses are highly immunogenic. They activate the innate immune 
system presumably by expressing so-called pathogen-associated 
molecular patterns (PAMPs), induce maturation of dendritic cells 
(Medzhitov et al., 2000), but principally enhance cellular immunity. 
In preclinical models, these vectors are shown to induce potent 
transgene-specific T and B cell response. T cells are mainly CD8+ T 
cells though low CD4+ T cell responses of the Th1 are also induced (He 
et al., 2000). 
Most importantly, head to head comparisons with other genetic vaccines 
(i.e. poxviruses, lentiviruses, alpha virus-based vectors and naked DNA) 
in animal models and the results obtained in human clinical trials, 
including vaccines against Ebola, SARS, HIV and Anthrax clearly show 
that Ad5-based vectors represent the most potent currently available 
delivery system for eliciting a CD8 T cell response against the encoded 
antigens (Casimiro et al., 2003).   
Bassett et al (2011) demonstrate that unlike most acute infections, the 
CD8+ T cell memory population, elicited by persistent, low-level 
transgene expression from recombinant human adenovirus serotype 5, 
shows an effector memory phenotype. 
The memory population is composed of effector (TEFF; CD127- CD62L-) 
and effector memory (TEM; CD127+CD62L-) T cells with little evidence 
of central memory (TCM; CD127+ CD62L+) T-cell accumulation (Yang 
et al., 2006). 
Moreover, Adeno vectors have a natural aptitude for increasing innate 
immunity, thanks to the activity of their structural viral proteins. 
Different pathways, belonging to innate immunity, are implicated in the 
response against Adeno, including Toll-like receptors (TLRs).   
Indeed, Appledorn et al (2009) have evaluated the role of TLR pathway 
signaling in Ad-specific inductions of innate and adaptive immunity and 
have identified different TLR proteins that contribute to immune 
response. 
TLRs are type 1 transmembrane pathogen recognition receptor proteins 
that contain leucine-rich repeat extracellular domains and a cytosolic toll-
interleukin-1 receptor (TIR) homology domain that is essential for intra- 
cellular signaling. Upon activation, TLRs recruit TIR containing adaptor 
molecules, including myeloid differentiation primary response gene 88 
(MyD88) and TIR-domain-containing adapter-inducing interferon- 
(TRIF, also known as TICAM1).These two adaptor molecules have a 
critical role in mediating TLR signaling in a temporal manner and 
determine the production of different cytokines. 
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Using MyD88 and TRIF double knockout mice, Applendorn et al (2009) 
demonstrated that these adaptor proteins can play either additive or 
redundant roles in mediating certain aspects of Ad vector-induced 
immune responses. 
The improved ability of Adeno vectors to elicit immune response with 
respect to other vaccine formulations has been demonstrated by Shiver et 
al (2002). They have compared the immunogenicity of several vaccine 
vectors in three different formulations: DNA vector, modified vaccinia 
Ankara vector (MVA) virus and a replication incompetent adenoviruses 
type 5 (Ad5) vector expressing the SIV gag protein belong to simian 
immunodeficiency virus of rhesus monkey. They tested the vaccines 
either as a single modality or in combined modality regimens. They 
found that replication-incompetent Ad5 vector, used alone or as a booster 
inoculation after priming with a DNA vector induced the most potent 
response. Moreover, they showed that challenging animals previously 
immunized with Ad5 vector with a pathogenic HIV-SIV hybrid virus 
(SHIV), promoted a highly pronounced attenuation of the virus infection.  
 
Steffensen et al. (2012), also, demonstrated that a DNA-primed immune 
response can be effectively boosted by the Ad35 vector and that this 
response can be further boosted by Ad5 vector. This series of 
vaccinations leads to a memory CD8+ T cell population characterized by 
low CD27 expression and high CD127 and killer cell lectin-like-receptor 
subfamily G member 1 (KLRG1) expression. These memory CD8 T cell 
are able to proliferate in response to viral challenge and to protect against 
infection.  
Human adenoviruses vectors are attractive for several reasons.  
First, they possess a stable virion, wide cell tropism and the transferred 
information remains epichromosomal, avoiding the risk of insertional 
mutagenesis. Second, they are safe and can be propagated easily with 
good yields in complementing cells lines. Finally, compared to DNA 
vaccines, adenoviral vectors more efficiently enter in the transduced 
cells, especially APC cells and induce high level of protein expression.   
However, the majority of the human population is exposed to Ad5 in first 
years of life and develops high titer of anti-Ad5 neutralizing antibodies 
(nAb) against the adenovirus capsid. These pre-existing Ad5 nAb impair 
the immunogenicity of Ad5-based vaccines in animal models and 
humans and may also potentially compromise their safety.  
To overcome this drawback, several strategies are used including rare 
human adenovirus serotypes such as Ad11, Ad24, Ad26, Ad34, Ad35, 
Ad48, Ad49 and Ad50. All of these serotypes are rarely neutralized by 
antibodies present in humans and are currently being evaluated in a 
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number of pre-clinical and clinical studies (Abbink et al., 2007). 
However adeno vectors from different serotypes have lower 
immunological potency than Ad5 in mice and in non-human primates 
(Colloca et al., 2012). Another approach is to encapsulate adeno vectors 
in inert polymer or to use nonhuman adenoviruses, such as simian and 
porcine vectors. Indeed, Colloca et al., (2012) have generated a large 
collection of replication defective vectors based on Ad isolated from 
chimpanzees (ChAds). These types of vectors are strongly related to 
human Ads, showing high degree of DNA homology with human Ads 
belonging to the same species and similar genomic structure.  All ChAds 
which  reveal significant diversity in the hypervariable regions in the 
hexon protein from the highly sieroprevalent Ad5, are not neutralized in 
vitro and in vivo by anti-Ad5 antibodies and some of these have an 
equivalent immunological potency of Ad5 such as 
ChAd3,ChAd63,ChAd83,PanAd1,PanAd2 and PanAd3. Indeed two of 
the most potent ChAd vectors have been selected for clinical studies as 
carriers for malaria and hepatitis C virus (HCV) genetic vaccines 
(Colloca et al, 2012).  
ChAd63 encoding for pre-erythrocytic insert multiple epitope 
thrombospondin-related adhesion protein for malaria ME-TRAP, was 
tested in a phase I clinical study from 2007 to 2010. It was administered 
alone or in a prime-boost regime with a modified vaccinia virus Ankara 
(MVA) ME-TRAP 8 weeks later. At the end of the study, ChAd63 
resulted safe and highly immunogenic (O’Hara et al., 2012).  
In a recent study, two other adenoviral vector expressing NS proteins 
from HCV genotype 1b were constructed based on rare serotypes such as 
human adenovirus 6 (Ad6) and chimpanzee adenovirus 3 (ChAd3). They 
were tested in a phase 1 study of healthy human volunteers (Barnes et al., 
2012). Both vectors primed T cell responses against HCV proteins, by 
targeting multiple proteins and were able to recognize heterologous 
strains (genotypes 1A and 3A). HCV-specific T cell consisted of CD4 
and CD8 T cell, secreted IL2, IFNƔ and TNFα and was sustained for at 
least 1 year after boosting with heterologous adenoviral vector.  
Swadling et al (2014) assessed the immunogenicity of ChAd3 vector 
encoding for NS3, NS4, NS5A and NS5B proteins of HCV genotype 1b 
in a prime-boost regimen with MVA virus in healthy human volunteers. 
The specific T cell response, elicited after prime, was optimally boosted 
with MVA, generating high level of CD4+ and CD8+ T cells targeting 
multiple HCV antigens. Furthermore, elicited T cells showed a effector 
memory phenotype that evolved over time with improvement of quality 
after boost.  
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Altogether, these preclinical studies highlight that an adenovirus prime 
followed by an MVA boost is a powerful strategy to induce a strong and 
durable T cell response.  
 
1.3.4 Improve immunogenicity of viral vector-based vaccines 
 
Different strategies had been explored to improve immune response 
against antigens inserted in DNA and viral-vectored vaccines. Improved 
responses might be needed to reduce the dose of the vaccine or the 
number of injections; and to improve the efficacy of vaccines in 
newborns, the elderly, and immunocompromised people. 
Strategies employed to enhance immunogenicity of DNA vaccines 
included: 1) addition of CpG sequences in the vector to increase its 
immunological propriety; 2) maximize the antigen presentation using 
strong constitutive promoters by adding regulatory elements that work as 
transcriptional enhancers or by optimizing the codon usage of the antigen 
sequence; 3)  co-administration of  DNA with cytokine such as IL-2, IL-
23, or GM-CSF to boost  immunization with genes encoding protective 
antigens much more effective; 4) co-administration of DNA with lipid 
complexes, micro particles or other delivery formulations to increase 
transfection and expression efficacy (Cheung et al., 2004; Barouch  et 
al.,2005). 
Another approach to improve immune response after DNA vaccine is to 
use signal sequences that target the antigen to intracellular compartments. 
For example, the invariant surface glycoprotein (ISG) and the N-terminal 
trans-sialidase (nTSA) of Trypanosma brucei were used as an antigen 
model by Silva et al., 2009. In their study, the authors fused three 
different targeting sequences to the antigens such as secretion signal and 
lysosomal-associated membrane protein (LAMP-1) sequence (Ahlen et 
al., 2007; Ulmer et al., 2006).   
It is also possible to co-express the immunogen protein and the cytolytic 
protein, perforin (PRF), a protein of 67kda which upon degranulation, 
that leads to a non-apoptotic cell death. This strategy is adopted for 
human immunodeficiency virus-1 (HIV) Gag protein, a model antigen 
luciferase or HCV proteins after intradermal DNA vaccination (Gargett 
et al., 2014; Gummow et al., 2015).  
Bartholdy et al (2003) demonstrated that the linkage of MHC class I 
restricted epitopes of lymphocytic choriomeningitis virus covalently 
linked to human β2 microglobulin (β2m) in a DNA vaccine results in a 
major presentation of the inserted epitope covalently fused to the MHC 
complex. Mice vaccinated with the DNA vaccine encoded for epitope 
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linked to β2m show stronger recall response than mice vaccinated with a 
conventional mini-gene construct that codifies for an immunodominant 
peptide from a given pathogen.  
The same results were obtained by Holst et al (2007) using recombinant 
replication deficient adenovirus to express either full-length protein or 
minimal MHC class I restricted epitopes from lymphocytic 
choriomeningitis virus (LCMV). These authors demonstrated that 
minimal immunodominant epitope covalently linked to β2-microglobulin 
determines a CD8+ T cell response that is faster and more consistent than 
the CD8+ T cell response induced by the full length viral glycoprotein. 
The generated CD8+ T cells provide long-term protection from virus 
infection, thus adding support to the role of CD8 T cell-memory in 
protection from lethal infection. 
This strategy uses an Ad5 vector encoding for a TLR agonist derived 
from Eimeria tenella (EA) as an adjuvant linked to HIV-Gag. The 
expression of rEA elicits TLR mediated innate immune responses by 
evaluating the production of chemokines or cytokines and activation of 
the innate immune system in mice (Appledorn et al., 2010).  
Other approaches are based on linking to the antigen the herpes virus 
VP22 protein and calreticulin which have been tested in Sindbis virus 
replicon particles (Cheng et al., 2002) and vaccinia vectors (Hsieh et al., 
2004), and the herpes viral glycoprotein D, which has  been tested using 
Ad vectors (Lasaro et al., 2008).  
Since viral vectors are good inducers of CD8+ T cell response and the 
ubiquitination has an important role in the processing of antigens loaded 
in MHC class I molecules, several vaccine strategies could exploit it to 
increase antigen presentation.  
Rodriguez et al (1997) set out a DNA transfection experiment using a 
plasmid encoded LCMV viral antigen linked to ubiquitin molecule at its 
N terminus. They showed an enhanced intracellular degradation of 
LCMV nucleoprotein (NP) thanks to the linkage of ubiquitin. The 
ubiquitinated NP is hardly detectable at steady state, but is easily 
visualized after proteasome inhibition using ALLN inhibitor, suggesting 
a rapid turnover of ubiquitinated protein and an important role of 
proteasome in degradation of the ubiquitin-tagged proteins. In vitro 
cytotoxicity assay, using MC57 (MHC haplotype b) and BalbCl7 (MHC 
haplotype d) cells transfected with DNA plasmids encoding for NP and 
Ub-NP and splenocytes derived by mice infected with LCMV virus as 
effector cells showed that the presence of ubiquitin-NP products led to an 
improvement of MHC class I presentation, since transfected tissue 
culture cells are more sensitive to CTL lysis. Further mice immunized 
with plasmid DNA encoding this rapidly degraded protein are able to 
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mount an enhanced antiviral CTL induction and protective antiviral 
immunity. Bazhan et al (2010) designed DNA vaccines encoding for ten 
selected HLA-A2 epitopes from the major HIV antigens evaluating also 
different approaches to improve their immunogenicity through the 
linkage of ubiquitin molecule to the N terminus of poly-epitope to 
increase the targeting to proteasome, or use spacer sequences between 
epitopes to optimize proteasome liberation and TAP transport. After a 
first in vitro analysis, they assessed the immunogenicity of these 
constructs through double DNA prime and single vaccinia virus boost 
immunization of HLA-A2 transgenic mice. They showed that most 
immunogenic vaccine construct contained the N-terminal ubiquitin for 
targeting the poly-epitope to the proteasome and included both 
proteasome liberation and TAP transport optimized spacer sequences that 
flanked the epitopes within the poly-epitope construct. 
Reguzova et al (2015) designed novel HIV poly-epitope T cell 
immunogens based on conserved natural CD8+ and CD4+ T cell epitopes 
from different HIV strains and restricted by most major HLA alleles.  
Designed immunogens contained optimized core poly-epitope sequence 
and additional sequences such as N terminal ubiquitin or N-terminal 
signal peptide, and C-terminal tyrosine motif of LAMP-1 protein that 
increase epitope processing and antigen presentation.  So far they 
engineered three DNA vaccines, by encoding novel T cell immunogens 
and different combination of signal sequences.  
All constructs have been tested in vivo and the attachment of either 
ubiquitin or ER signal/LAMP1 sequences increases both CD8+ and 
CD4+T cell response in comparison with poly-epitope immunogen 
without any additional sequences, but the linkage of ubiquitin to 
immunogen core determined an highest magnitude of T cell responses.  
 
 
1.3.5  Invariant chain as genetic adjuvant 
 
The generation of high quality memory cells together with the induction 
of a substantially expanded CD8+ T cell population is possible by linking 
the major histocompatibility complex class II associated invariant chain 
(Ii) to an antigen encoded by an adenoviral vector.    
Holst et al (2008) have demonstrated that an adenovirus expressing the 
glycoprotein (GP) of the lymphocytic choriomeningitis virus (LCMV) 
tethered to Ii increases the kinetics, magnitude and durability of T cell 
specific responses in vivo. 
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Ii was initially used with the aim to improve CD4+ T cell response when 
linked to an antigen. Malcherek et al (1998) have engineered a Ii vector 
by inserting T cell epitopes of tetanus toxin or acetylcholine receptor in 
the CLIP region. When peripheral blood mononuclear cells (PBMC) are 
pulsed with Ii hybrids T cell response is increased compared to 
stimulation after priming with native or recombinant proteins. Fujii et al 
(1998) also designed a mutated human form p33 in which they 
substituted CLIP with streptococcal M12 p55-68 and evaluated the 
peptide presenting function through a T cell proliferation assay. Mouse L 
transfectants expressing mutated form of Ii with HLA-DR4 can process 
and present M12 p55-68 to the peptide specific and DR4 restricted CD4+ 
T cell clone.  
Another method to increase antigen-specific stimulation of T-helper cells 
entails the use of the Ii hybrids, in which a four-amino-acid sequence 
(LRMK), the KEY motif of Ii, is linked to T-helper epitopes. The 
mechanistic hypothesis states that the Ii-KEY binds initially to an 
allosteric site just outside the MHC class II binding groove at the cell 
surface (Voutsas et al., 2007). This induces a conformational change in 
the trough, facilitating antigenic epitope charging, and a concomitant 
increase in the potency of antigen presentation compared with the 
unmodified class II epitope. As vector, Ii-KEY and Ii enhanced the 
interferon IFNγ and interleukin IL-4 or IL-2 responses in enzyme-linked 
immunosorbent spot assay, epitope-specific CD4+ T cell activation, or 
specific antibody production (Chen et al., 2012). 
In addition, Mwangi et al (2007) have designed a DNA-construct 
encoding for the major surface protein 1a of Anaplasma marginale fused 
with the lysosome-targeting motif of bovine Ii. A single inoculation with 
this construct primed immune response seen as a potent proliferation of 
IFN-Ɣ/CD4 T cells and production of IgG. A single injection of this 
construct induced antigen specific memory cells, which formed the basis 
for an accelerated response to repeated doses of the antigen.  
The linkage of Ii to the N terminus of glycoprotein of LCMV virus 
encoded by Adenovirus-based vaccines induced enhanced proliferation 
of naïve CD4+ and CD8+ T cells determining an accelerated, enhanced 
and prolonged vaccine-induced protection against acute or chronic viral 
infection. Additionally, this vaccine provides efficient protection against 
viral escape variants due to an increased breadth of the vaccine-induced 
CD8+ T cell response (Holst et al., 2008). 
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Likewise, the adjuvant effect of Ii is obtained when Ii is linked to NS3, a 
nonstructural protein from HCV and the fusion is encoded by Adeno 
vector. Ad-murine-Ii NS3-induced CD8+ T cells show increased 
cytotoxicity compared to Ad NS3. In addition, Ad li-NS3 elicited high 
quality memory cells characterized for being poly-functional (IFNƔ, 
TNFα and IL2) central memory T cells expressing the phenotypic cell 
surface markers CD27 and CD127. These markers are associated with 
long-term survival of Ag-specific memory CD8+ T cells and 
maintenance of T cell memory (Mikkelesen et al., 2011). 
Ii does not only enhance CD8+ T cell responses when tethered to antigen 
within Ad vectors but has been shown to enhance responses when 
included in DNA plasmids, lentiviral vectors and MVA.  
Indeed, Rowe et al (2006) constructed lentiviral vaccine vectors carrying 
Ii sequence linked to chicken ovalbumin, as model antigen. The Ii-OVA 
vector was the most efficient at inducing cytokine-secreting CD4+ and 
CD8+ T cells in mice and at protecting mice from challenge with the 
OVA-expressing tumor, EG7.OVA.  
The enhanced T cell response is visible also when murine p31 Ii is linked 
to naked DNA encoded antigens. Grujic et al (2009) compared two DNA 
vaccines, pACCMV.pLpA expressing either the glycoprotein (GP) of 
LCMV virus (DNA-GP) or GP linked to the p31 Ii chain (DNA Ii-GP) 
after gene immunization through FACS analysis. The insertion of the 
murine Ii chain at the N terminus of GP antigen results in increased 
priming of antigen specific CD8+ T cells directed against both dominant 
and subdominant epitopes as previously described by Holst et al (2008) 
using Adeno5 vaccine vector. Further they demonstrated that DNA mIi-
GP vaccinated mice were significantly better protected against systemic 
infection than DNA-GP vaccinated animals.  
The enhanced protection derived by Ii has also been demonstrated in a 
murine cancer model where the vaccination becomes a tool to improve 
cancer specific T cell responses and vaccine-induced tumor control. In 
brief, C57BL/6 mice are challenged with B16.F10 melanomas expressing 
the dominant epitope (GP33) of LCMV glycoprotein and vaccinated with 
Ad5 Ii GP.  Vaccination with Ad5 Ii GP leads to a sustained rejection of 
the tumor in mice vaccinated prior to tumor challenge and a delay of 
tumor growth in therapeutically vaccinated mice compared to Ad5 GP 
(Sorensen et al., 2009). 
The effect of Ii was seen for both murine and human form of Ii and was 
observed in inbred and outbred mice (as described previously) and in 
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cynomolgus macaque as described by Capone et al (2014). They 
demonstrated that fusion to murine Ii in CD1 mice and NHP improves 
the magnitude and the breadth of CD8+ T-cell response to vaccine-
encoded homologous and heterologous HCV NS antigen in a prime-boost 
regime using a chimpanzee Adeno vector (ChAd3) as primer and MVA 
virus as booster. Since HCV virus exists in six different genotypes and 
accumulates mutations, during its replication, this poly-specific elicited 
response facilitates targeting multiple epitopes from divergent HCV virus 
genotypes. Like the murine version of Ii, the human form of Ii 
accelerated a CD8+ specific T cell response in both animal models. 
Despite macaque Ii has very high amino acid sequence homology with 
human p35 form of Ii, no self-reactive T cells of Ii were detected. This 
demonstrates that the enhancement, derived by Ii, is not species specific 
and translates from mice to NHP.    
 The same results were obtained by Spencer et al (2014) when they tested   
in a regime of prime boost, the adjuvant effect  of murine and human Ii 
linked to ME-TRAP, an antigenic construct encoded for full length 
Plasmodium falciparum TRAP (thrombospodin related adhesion protein) 
fused to ME, a string of 20 malarial T and B cell epitopes. In particular, 
after prime-boost vaccination with ChAd63 and with a subsequent MVA  
boost ( given 8 weeks later), they observed a significantly higher antigen 
specific CD8+ T cell response in mice and macaques than in those 
expressing unmodified ME-TRAP.  
In other studies, Ii shows protection not only by challenge with virus but 
also by intracellular bacteria, such as Listeria monocytogenes Gram 
positive bacteria that cause chorioamnionitis in pregnant women and 
septicemia and meningitis in immunocompromised individuals.. To 
effective clear this infection, the host elicits an adaptive immune 
response involving both CD8+ and CD4+ T cells.  For this reason, Jensen 
et al (2013) tested two Adeno vectors expressing the glycoprotein of 
LCMV virus (GP) with and without the Ii linkage. After vaccination with 
Ad5 Ii GP and Ad5 GP, mice are challenged with a recombinant strain of 
Listeria monocytogenes modified to secrete part of LCMV GP. The 
tethering of Ii to antigen conferred protection in mice vaccinated with 
Ad5 Ii GP than with Ad GP.  
Despite the extensive description of the adjuvant effect of Ii, the 
molecular mechanisms underlying this effect have not yet been 
elucidated.  
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2. AIM OF THE STUDY 
 
My research activity, during the last three years, focused on identification 
of the mechanism of action of Invariant chain as genetic adjuvant in the T 
cell response induced by adenoviral vectors used as vaccines.  
Ii is a non-polymorphic type II trans-membrane protein, first identified as 
the chaperone for MHC class II molecules (Blum et al., 2013) and 
prevents the premature binding of antigen peptides in the ER on class II 
molecules. Although Ii plays a role to ensure a CD4+ T cell response, its 
genetic fusion of Ii to antigens encoded by human adenoviral vectors 
(such as Ad5) increases the kinetics, magnitude and durability of CD8 T 
cell response (Holst et al., 2008).  
The adjuvant effect of Ii has been demonstrated linking as the murine as 
the human forms of Ii to several antigens, such as malaria, Ebola, HCV 
and LCMV viruses in inbred and outbreed mice and non-human primates 
(NHP) (Malcherek et al., 1998; Holst et al., 2008; Capone et al., 2014; 
Spencer et al., 2014). 
Despite the extensive characterization of the effect of Ii as genetic 
enhancer of CD8+ T cell response, its mechanism of action still remains 
unknown. 
For this reason my research activity was devoted to identify the 
functional domains of Ii involved in enhanced CD8+ T cell response and 
meanwhile to define the minimal region of the Ii that could retain 
adjuvant effect. 
Trimming of Ii to very short functional sequences might offer a better 
candidate for evaluation of this technology in humans reducing possible 
off target effects within transduced cells or improve the chances of 
breaking tolerance. 
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3   MATERIALS    AND   METHODS 
3.1 Cell line cultures 
Hela cells (ATCC) were cultured in Dulbecco’s Modified Essential 
Medium (DMEM) (GibcoBRL) supplemented with 10%  Fetal Bovine 
Serum (FBS) (heat inactivated 56°C 30 min Hyclone) and 2mM L-
glutamine (GibcoBRL) at 37°C in a 5% CO2/95% air atmosphere.  
BMDC (Bone Marrow Dendritic Cells) were obtained from femurs of 6-
10 week old female CB6F1 mouse. The protocol for generation and 
purification of BMDC was adapted from Muccioli et al., 2011. The ends 
of the bones were cut off and the inside of the bones infused with RPMI 
using a sterile syringe inside a petri dish. Bone marrow leukocytes 
clumps were broken up and the cell suspension washed twice in RPMI  
(GibcoBRL) containing with 10% FBS (Hyclone), 2mM L-glutammine 
(GibcoBRL), 10mM Hepes (GibcoBRL), 55µM 2-mercaptoethanol 
(GibcoBRL) (1200 rpm for 5 minutes) after collection. Red blood cells 
were lysed using ACK lysis buffer (5 minutes RT) and washed with 
RPMI and counted. 3 x106 cells were cultured in 10ml R10% in a T75 
flask (BD 353136) with 10 ng/ml of recombinant murine granulocyte-
macrophage colony-stimulating factor (rGM-CSF; Invitrogen PMC2015) 
at 37°C with 5% CO2. On day 3 cultures were supplemented with 10mls 
of R10 with 10 ng/ml rGM-CSF. On day 6 of culture the media was 
harvested, cells were pelleted (1200 rpm for 5 minutes) and suspended in 
20ml of fresh R10 supplemented with 10 ng/ml rGM-CSF until 10 days.  
For the last part of experiments it was used another protocol to 
differentiate BMDC cells in suspension (Zanoni et al., 2011). 7 x106 cells 
were cultured in 10ml R10% in a T75 flask (Corning 3814) with 10 
ng/ml of recombinant murine granulocyte-macrophage colony-
stimulating factor (rGM-CSF; Invitrogen PMC2015) at 37°C with 5% 
CO2. On days 4 and 7 5 ml of R10 with 10 ng/ml rGM-CSF were added 
and cells grew until day 8/9.  
The new protocol was introduced to achieve a better differentiation and 
viability of BMDC cells in vitro and to collect a high number of cells for 
each experiment. The results obtained with two protocols were 
comparable. 
HuH7 and HEK293 (ATCC) were grown in DMEM supplemented with 
10% FBS (Hyclone) and 2mM L-glutamine (GibcoBRL) at 37°C in a 5% 
CO2/95% air atmosphere 
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3.2 Adenoviral vectors: construction, amplification and purification 
The first adenoviral vectors were made by Peter Holst (University of 
Copenhagen). Murine Ii (mIi) insert (accession number NM_1042605.1) 
was obtained from plasmid murine Ii opt. 
 All Ad constructs were E1E3 deleted and all full and truncated Ii 
sequences were cloned at the N-terminus of the transgene under HCMV 
and SV40pA. 
For the second part of the work, the new short variant mIi 50-75 OVA , 
the mutated vectors in the full length and in the short forms and related 
controls such as Ad5 OVA, Ad5 mIi OVA or Ad5 1-75 mIi OVA were 
generated by me using another preAdeno shuttle.  
GeneArt (Life Technologies, Paisley, UK) had synthesized pvj plasmid 
encoded for mutated and short variants of mIi using pvj shuttle. 
All full and truncated Ii sequences were cloned at the N-terminus of the 
transgene OVA under HCMV and BGHpA control and then transferred 
into the pre-adeno vector by homologous recombination in BJ5183 cells. 
All Ad constructs were E1E3 deleted and therefore non-replicative 
except in E1 supplemented cell lines.  
The first pre-adeno backbone and the last one differed for the poly A 
signal and also for the length of the HCMV promoter.  
The sequence of HCMV promoter of the first pre-adeno backbone is: 
5’GATCTATACATTGAATCAATATTGGCAATTAGCCATATTAGTCA
TTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATAC
GTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA
TATGACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGT
AATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCC
GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCC
AACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCAT
AGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAG
TATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT
ATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC
CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTA
CTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGA
TGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGA
CTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGG
AGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTC
GTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGT
ACGGTGGGAGGTCTATATAAGCAGAGCTC 3’ 
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The sequence of HCMV promoter of the second pre-adeno backbone is: 
5’CCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATT
GGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACT
AGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCA
TATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCT
GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGA
CGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGT
CAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACA
TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG
ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA
TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGG
ATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTG
ACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTT
TCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGC
GGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCC
CTATCAGTGATAGAGATCTCCCTATCAGTGATAGAGATCGTCGA
CGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATC
CACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAG
CCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGT
GCCAAGAGTGAGATCTTCCGTTTATCTAGGTACCAGATA 3’ 
 
The second pre-adeno backbone had a longer promoter than the first one. 
Probably this justified difference in the vaccination dosages. 
The change of backbone had been useful to verify if the phenotype that it 
is visible in vivo between OVA and mIi OVA, is independent from 
transcriptional regulation signals such as promoter and polyA.  
Pre-adeno plasmids were first digested with PmeI to release the viral 
ITRs then 3-5×106 HEK293/PER.C6 cells grown in DMEM, 10% fetal 
bovine serum (FBS), 1% Penn-Strept in T25 flasks, were transfected with 
10 micrograms of cloned viral vector. DNA transfection was performed 
using Lipofectamine 2000 (Invitrogen). Vectors were then expanded up 
to a production scale of 2×109 cells. Purification was performed by two 
step Cesium Chloride gradient (Colloca et al., 2012).  All viruses were 
controlled by restriction and sequencing analysis. 
3.3 Animal and vaccination   
All experimental procedures were approved by the local animal ethics 
council and were performed in accordance with national and international 
laws and policies (EEC Council Directive 86/609; Italian Legislative 
Decree 116/92). The ethical committee of the Italian Ministry of Health 
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approved this research. Animal handling procedures were performed 
under anesthesia, and all efforts were made to reduce animal numbers 
and minimize suffering. Six-week-old female C57 mice were purchased 
from Charles River (Como, Italy). All day-to-day care of the mice was 
performed by trained mouse house staff at CEINGE. Viral vectors were 
administered with intramuscular injection in the quadriceps by delivering 
a volume of 50 µl per side (100 µl final volume). The injected dose for 
all mouse experiments was 3×106 viral particles (vp) for Ad vectors. For 
the second part of the project the dose of injection was 106 vp.  
3.4 Ex vivo IFN-Ɣ ELISpot 
Mouse splenocytes were plated in duplicate at two different densities (2x 
105 and 4 x 105 cells per well) after blocking e washing of MSIP S4510 
plates (Millipore , Billerica, MA) coated with 10 µg/ml of anti- mouse 
IFN-Ɣ antibody (U-CyTech Utrecht, The Netherlands) overnight at 4°C. 
The cells were stimulated overnight at 37°C with immunodominant OVA 
peptide 257-264 (SIINFEKL) at a final concentration of 2µg/ml on each 
well.  Two controls were used in this assay: the peptide diluent dimethyl 
sulfoxide (Sigma- Aldrich, Milan, Italy) as negative control and 
concanavalin A (Sigma- Aldrich, Milan, Italy) as positive control. Plated 
were incubated with biotinylated anti-mouse IFN-Ɣ antibody (U-CyTech 
Utrecht, The Netherlands) conjugated streptavidin-alkaline phosphatase 
(BD Bioscience, San Jose, CA) and at the end with 5-bromo-4-chloro-3-
indoyl-phosphatase/nitro blue tetrazolium 1-step solution (Thermo Fisher 
Scientific, Rockford , IL).  An automated ELISA –spot assay video 
analysis system automated plate reader was used to analyze plates. The 
ELISpot data were expressed as number of T cells producing IFN- Ɣ per 
millions of splenocytes. To have a positive ELISpot response these 
following conditions must occur: IFN- Ɣ spots present in wells stimulated 
with Con-A; at least 50 specific spots/million splenocytes  to 
immunodominant peptide; the number of spots of positive wells was 
three times the number identified in the mock control wells (dimethyl 
sulfoxide) and responses diminished with cells dilutions. 
3.5 Infection 
Hela cells were stripped from the plate using pre-warmed trypsin (0.05% 
GibcoBRL 25300-054) and were infected with adenoviral vectors in 
DMEM containing 2% FBS and 2mM L-glutammine (GibcoBRL) at 100 
MOI (Multiplicity Of Infection-vp/cell) for Western blot analysis (106 
cells), 50 MOI (vp/cell) for immunoprecipitation (3x106 cells) and FACS 
analysis (106 cells) and 50 MOI for immunofluorescence (105 cells). 
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After 1 hour the cells were added with DMEM with 10% FBS. After 3 
hours the cells were treated with appropriate inhibitors for 16 hours such 
as MG-132 (10µM Sigma), pepstatin (1µM)/ E64D (10µM) (ratio 1:1), 
chloroquine (500nM), radicicol (90µM) (Hsp90 inhibitor) and 17-
allylamino-17demethoxy-geldanamycin (17-AAG 170nM) (Hsp70/90 
inhibitor).  
BMDC cells were stripped from the plate using pre-warmed trypsin 
(0.25% GibcoBRL 25200-056) and cell dissociation solution (Sigma, 
C5789-100ml) 1:1 mix (incubated 7 minutes in a CO2 incubator at 37°C 
and 5% CO2) and were infected in 48 well- plate with adenoviral vectors 
in RPMI containing 2% FBS and 2mM L-glutammine (GibcoBRL) at 
200 MOI (infection units/cell) (2x105 cells). After 1 hour the cells were 
added with RPMI with 10% FBS. After 3 hours the cells were treated 
with MG-132 inhibitor and pepstatin (1µM)/ E64D (10µM) (ratio 1:1) 
for 16 hours. 
For immunofluorescence analysis HuH7, HEK293 and BMDC cells (105 
cells) were infected with a dose escalation of MOI (5-10-50 MOI). 
 
3.6 Immunoprecipitation for ubiquitination analysis 
 
For the ubiquitination analysis Hela cells were transfected with Ub-
FLAG plasmid (Invitrogen) (2µg) for 16 hours with Lipofectamine 2000 
(Invitrogen) according to the manufacture instruction. After change of 
medium, the cells were infected with adenoviral vectors for 16 hours and 
treated with MG-132 for 24 hours. The Hela cells were lysed and the 
protein lysates were immunoprecipitated with anti-UbLys48 antibody (10 
µg clone Apu2 rabbit monoclonal Millipore) or with anti Ub-Lys63 
antibody (10 µg clone Apu3 rabbit monoclonal Millipore) for 16 hours at 
4°C with rocking. After the supernatants were incubated with protein A 
sepharose CL-4B (500 µg GE Healthcare) for 45 minutes at 4°C with 
rocking. The samples were analyzed by Western blot. 
 
3.7 Analysis of PNGase activity                                                                
Protein lysates were immunoprecipitated with anti GFP (2µg mouse 
monoclonal clone B-2 Santa Cruz) or with anti HA (2µg rabbit 
polyclonal Sigma) for 16 hours at 4°C with rocking. After the 
supernatants were incubated with protein A sepharose CL-4B (500 µg 
GE Healthcare) for 45 minutes at 4°C with rocking. The samples were 
treated with 0,2% SDS in 75mM sodium phosphate buffer pH7.5, boiled 
(95°C for 5 minutes) and reduced with  DTT. After they were treated 
with 2% Tryton in 75 mM sodium phosphate buffer (pH 7.5) and 
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inhibitors protease and digested with PNGase enzyme (1000U for each 
sample Biolabs) for 3 hours at 37°C. This enzyme is an amidase which 
cleaves between the innermost GlcNAc and asparagine residues of high 
mannose,hybrid and complex oligosaccharides from N-linked 
glycoproteins. At the end of incubation lysates were resolved with 
Western blot analysis.  
3.8 Western blot analysis 
 
The Hela cells were lysed in 20mM Tris-HCL pH7.5, 150mM NaCl and 
1mM EDTA pH8 and cell debris was removed by centrifugation (13000 
rpm for 30 minutes). Lysates were resolved by 4-12% SDS PAGE and 
transferred to nitrocellulose membrane. The membrane was probed with 
anti GFP-HRP (mouse monoclonal anti –Green Fluorescent Protein-
Horseradish Peroxidase Miltenyi Biotec 1:5000), anti HA –HRP( mouse 
monoclonal anti –Hemmagglutinin-Horseradish Peroxidase Miltenyi 
Biotec 1:5000), anti GFP (mouse monoclonal clone B-2 Santa Cruz 
1:1000), anti-FLAG (mouse monoclonal clone M2 Sigma 1:5000) anti 
GAPDH (mouse monoclonal Sigma-Aldrich 1:3000) and peroxidase-
conjugated anti-mouse( A3682, Sigma-Aldrich, 1:5000). The blot was 
visualized using ECL (SuperSignal West Pico Chemiluminscent substrate 
Thermo scientific). To quantify the relative amounts of the 
immunolabeled bands, different exposures of the blot were analyzed with 
the NIH image program.  
 
3.9 Antigen presentation assay 
After transduction BMDC are harvested as above, washed in RPMI 
twice, and suspended in PBS. BMDC are pelleted and suspended in PBS-
Fc blocked (1:25 BD Bioscience) at 4°C for 20 minutes. After wash in 
PBS, the pellet was suspended in violet fixable live/dead (1:50 by 1:20 
dilution Life Technologies) and stained at room temperature for 20 
minutes. Cells were washed with PBS and incubated with CD11c-Pecy7 
(1:100 BD Bioscience) and H2-Kb-SIINFEKEL (1:100 Biolegend) in 
FACS buffer (1% FBS in PBS) for 30 minutes at room temperature. 
After centrifugation at 1200 rpm for 5 minutes, the pellet was washed in 
FACS buffer and suspended in PBS. Stained cells were acquired on a 
FACS Canto flow cytometer and analyzed using DIVA software (BD 
Biosciences). Voltages and gating were checked with BMDC infected 
with Ads containing full length mIi and unstained and not infected cells.   
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3.10 FACS analysis  
Hela cells (2x105) were transfected with DNA encoded GFP or mIi GFP 
(0.8 ug) or infected with adenoviral vectors encoding for GFP as 
described above. After 4 hours they were treated with MG-132 (10µM 
Sigma), chloroquine (1x) and pepstatin (1µM)/E64D (10µM) (ratio 1:1), 
for 16 hours. Cells were harvested and suspended in violet fixable 
live/dead (1:50 by 1:20 dilution) at room temperature for 20 minutes. 
After incubation cells were washed with PBS. Stained cells were 
acquired on a FACS Canto flow cytometer and analyzed using DIVA 
software (BD Biosciences). Voltages and gating were checked with Hela 
infected with Ads containing full length mIi (or transfected with the same 
DNA form) and unstained and not infected cells.   
3.11 Immunofluorescence and colocalization evaluation 
Hela, BMDC, HEK29 and HuH7 cells (105 cells) were infected with 
50MOI or dose escalation of MOI (5-10-50 MOI) with Ad5 GFP or Ad5 
mIi GFP and treated or not with MG-132 for 24 hours. 
Poliethylenimmine (PEI) in water (1ug/ul) was used at transfecting agent. 
Briefly 2 ug of DNA were mixed with 5 ug of PEI in 150 mM NaCl to be 
then added after 30 minutes of incubation to a 10 cm dish of the cells in 
complete fresh medium. After detaching with 0,05% of trypsin, the cells 
were plated on glass coverslips and were fixed in 4% Formaldehyde 
dissolved in PBS for 30minutes. Formaldehyde was quenched by 
incubating the coverslips for 30minutes in 0,1M Glycine dissolved in 
PBS. Cells were permeabilized in 0, 1% TritonX100 for 10minutes at RT 
to be then incubated with primary and secondary antibody diluted in PBS 
for 1hour and 30minutes, respectively. The fluorescence of GFP was 
evaluated with confocal microscopy 
For co-localization study the antibodies used were:  rabbit polyclonal anti 
GM130  ( Sigma 1:100), rabbit polyclonal anti Lamp1 ( Thermo fisher 
1:200), rabbit polyclonal anti LC3 ( Abcam 1:50) and mouse monoclonal 
anti FLAG ( Sigma 1:100) that recognizes the FLAG tag linked to 
Ubiquitin FLAG plasmid, transfected in the cells (as described above). 
The secondary antibody was a rabbit Texas-Red conjugated polyclonal 
antibody (1:400 Sigma).  The immunofluorescence intensity in the 
Texas-Red channel (depending only on the PM localized CB1) was 
measured using NIH ImageJ Biophotonic programs and normalized to 
one of the GFP channel. The results are given as mean +/− s.d.m. 
Immunofluorescence images were taken by a Leica DFC320 video-
camera (Leica, Milan, Italy) connected to a Leica DMRB microscope 
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equipped with a 100 X objective and the Image J Software (National 
Institutes of Health, Bethesda, MD) was used for analysis. 
3.12 Statistical evaluation 
Statistical analysis was performed using GraphPad Prism (version 6). 
Because populations were more or less normally distributed, a parametric 
one-tailed unpaired Student’s t-test was used to evaluate statistical 
significance (*p <0,05; **p <0,01;***p <0,001; ****p <0,0001). 
One-tailed tests are appropriate when testing a specific, directional 
hypothesis. Because our a priori predictions, supported also by a lot of 
works presented in literature, were directional towards an improvement 
of T cell response thanks the presence of Ii, one-tailed tests were used.  
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